ホームページ Transmembrane Transporters TRP Channel agonist Cinnamaldehyde For research use only.

Cinnamaldehyde

Cinnamaldehyde is a flavonoid that is naturally synthesized by the shikimate pathway. Its supplementation can improve glucose and lipid homeostasis in diabetic animals; a TRPA1 agonist.

Cinnamaldehyde化学構造

CAS No. 14371-10-9

サイズ （液体） 価格(税別) 在庫状況
JPY 23100 国内在庫あり
JPY 216600 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例（2）

製品安全説明書

現在のバッチを見る： S376301 純度： 98.41%
98.41

Cinnamaldehyde関連製品

TRP Channel阻害剤の選択性比較

生物活性

製品説明 Cinnamaldehyde is a flavonoid that is naturally synthesized by the shikimate pathway. Its supplementation can improve glucose and lipid homeostasis in diabetic animals; a TRPA1 agonist.
Targets
TRPA1 [2]
In Vitro
In vitro Cinnamaldehyde (40 μM) could enhance the expression of hormone-sensitive lipase (HSL), and suppress the expression of perilipin and glycerol-3-phosphate dehydrogenase as well as reduce adipocyte genes expression of peroxisome proliferator-activated receptor (PPAR)-γ and CCAAT/enhancer-binding protein-α (CEBP-α) in 3T3-L1 pre-adipocytes. It also increases expression of PPARδ and PPARγ as well as its targeted genes such as aP2 and CD36 in 3T3-L1 differentiated adipocytes. Cinnamaldehyde (40 μM) treatment increases GLUT4 expression via activating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and triggering its downstream effector myocyte enhancer factors 2 (MEF2) in C2C12 cells. Its treatment regulates oxidative metabolism through increasing expressions of 5'-adenosine monophosphate-activated protein kinase (AMPK), NAD+-dependent deacetylases sirtuin 1, PGC-1α and cytochrome C as well as improving PPARα and PPARβ/δ expression, which contributes to mitochondrial biogenesis. However, cinnamaldehyde is demonstrated to inhibit mitochondrial metabolism by reducing basal and chemically-induced peak myotube oxidative metabolism in C2C12 cells[1]. Cinnamaldehyde exerts cytotoxic effects on human leukemia K562 cells by inducing apoptosis and synergizing the cytotoxicity of CIK cells against K562 cells[3].
細胞実験 細胞株 K562 cells
濃度 120 or 180 μmol/L
反応時間 4, 9, or 24 h
実験の流れ K562 cells are treated with various concentrations of TCA for 4, 9, or 24 h. Cells are harvested and labeled with Annexin V conjugated with fluorescein isothiocyanate (Annexin V-FITC) and PI. The cells are then analyzed by flow cytometry. Apoptotic cells are defined as Annexin V-positive and PI-negative cells (early apoptotic cells) plus Annexin V-positive and PI-positive cells (late apoptotic cells).
In Vivo
In Vivo Cinnamaldehyde exhibits glucolipid lowering effects in diabetic animals by increasing glucose uptake and improving insulin sensitivity in adipose and skeletal muscle tissues, improving glycogen synthesis in liver, restoring pancreatic islets dysfunction, slowing gastric emptying rates, and improving diabetic renal and brain disorders. Cinnamaldehyde exerts these effects through its action on multiple signaling pathways, including PPARs, AMPK, PI3K/IRS-1, RBP4-GLUT4, and ERK/JNK/p38MAPK, TRPA1-ghrelin and Nrf2 pathways. In addition, cinnamaldehyde seems to regulate the activities of PTP1B and α-amylase. Oral administration of cinnamaldehyde ranging from 20mg/kg to 40 mg/kg per day for a duration lasting from 21 to 60 days results in a significant improvement in the levels of blood glucose and glycosylated hemoglobin (HbA1C) as well as insulin sensitivity in STZ-induced diabetic rats. Cinnamaldehyde is not stable in the body, with the possibility of metabolizing into cinnamic acid and transforming into cinnamyl alcohol. Excessive doses of cinnamaldehyde may generate the toxic response. In human, 3% cinnamaldehyde may cause skin irritation. Cinnamaldehyde is demonstrated to decrease serum IL-1β and inhibit inflammatory gene expression (COX-2, MCP-1, TNF-α, and IL-6) in WAT of HFD insulted male Swiss albino mice and C57BLKS db/db mice, while increased expression of Cpt1a protects against pro-inflammatory adipokines release and promotes fatty acid oxidation, which contributes to an improvement in insulin resistance[1].
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05654298 Completed
Migraine
Universitaire Ziekenhuizen KU Leuven
 March 15 2022 Not Applicable
NCT04183283 Completed
Healthy
Eli Lilly and Company
 December 12 2019 Phase 1
NCT04415892 Recruiting
Chemotherapy-induced Peripheral Neuropathy
Universitaire Ziekenhuizen KU Leuven
 October 1 2019 Not Applicable

化学情報

分子量 132.16 化学式

C9H8O
CAS No. 14371-10-9 SDF Download Cinnamaldehyde SDFをダウンロードする
密度 1.05 g/mL at 25 °C
Smiles C1=CC=C(C=C1)C=CC=O
保管 2 years -80°C liquid

In vitro
Batch:

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Cinnamaldehydeを買う | Cinnamaldehyde ic50 | Cinnamaldehyde供給者 | Cinnamaldehydeを購入する | Cinnamaldehyde費用 | Cinnamaldehyde生産者 | オーダーCinnamaldehyde | Cinnamaldehyde化学構造 | Cinnamaldehyde分子量 | Cinnamaldehyde代理店